Deal Ends Today·Save 35% annual plan
Anabolic bone agent (PTH analog)Reviewed for 2026 plan year

Does Humana Cover Forteo?

The verdict

Conditional on most plans

Humana covers teriparatide for severe osteoporosis, but brand Forteo is frequently non-preferred on Medicare Part D plan drug lists — generic teriparatide injection or Bonsity is the covered option on most Humana formularies. If your plan does list brand Forteo, expect a specialty tier, prior authorization of 12–24 months, and documented failure or intolerance of a bisphosphonate. Unlike Humana's clean coverage of Prolia (a medical-benefit office injection), Forteo runs through the pharmacy benefit as a daily self-injected specialty drug — and brand status means higher cost-share or outright non-coverage.

MedicareConditional
CommercialConditional
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Humana using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Humana drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice

Key facts

  • Brand Forteo is frequently excluded from Medicare Part D formularies in favor of generic teriparatide injection or Bonsity — UHC and Cigna explicitly flag Forteo as 'typically excluded from coverage.' The same pattern applies broadly across major PBMs.

    CMS drug formulary guidance; KFF specialty drug coverage analysis

  • Teriparatide is a self-administered daily subcutaneous injection dispensed under the pharmacy benefit — unlike Prolia, which is a Part B medical-benefit clinic injection given every 6 months.

    FDA Forteo prescribing information; Eli Lilly

  • The 2026 Medicare Part D out-of-pocket cap of $2,100 applies to all covered Part D specialty drugs, including teriparatide — once reached, the member pays $0 for the remainder of the calendar year.

    CMS Medicare Part D 2026 benefit parameters; Inflation Reduction Act

Plan types

Medicare vs. commercial coverage

Whether Humana covers Forteo depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Conditional

Medicare Part D (operative pathway for most Humana members): teriparatide is on the specialty tier with prior authorization and a typical approval period of 12–24 months. Brand Forteo is frequently non-preferred in favor of generic teriparatide injection or Bonsity on Humana Part D formularies — check your specific Humana plan drug list to confirm whether brand Forteo or the generic is covered. When teriparatide is approved, expect 25–33% coinsurance after the deductible; the $2,100 (2026) Part D out-of-pocket cap limits annual exposure. The manufacturer's Lilly Cares savings program is NOT available to Medicare beneficiaries under federal anti-kickback rules. Humana Medicare Advantage plans integrate the Part D drug benefit — verify formulary status through your specific MA-PD plan. The $2,100 cap applies to the Part D pathway (unlike Prolia, which is a Part B drug where the cap does not apply).

Commercial / Employer

Group & marketplace plans

Conditional

Commercial/Employer: Humana's commercial book is limited. Where a Humana commercial plan exists, teriparatide is covered on the specialty tier with prior authorization; brand Forteo is often non-preferred versus generic teriparatide or Bonsity. Commercially insured patients may be eligible for Lilly's Forteo copay assistance program — verify directly with Lilly. ACA/Individual: limited Humana ACA presence; teriparatide covered with PA where offered; brand Forteo often non-preferred. Medicaid: Humana-managed Medicaid covers teriparatide per state preferred drug list with prior authorization and nominal cost-share; generic teriparatide or Bonsity is typically the preferred option per state PDL. Verify on your specific Humana plan documents.

Prior authorization

The 3 boxes you must tick to get approved

Commercial plans that will consider Forteo require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 3

Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Forteo actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

Brand Forteo is a high-cost specialty drug — list price is several thousand dollars per month (estimate; do not rely on this figure for planning; verify current pricing). Generic teriparatide injection and Bonsity are lower-cost preferred alternatives (estimate).

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Medicare Part D: 25–33% specialty coinsurance after the deductible (varies by plan design); the $2,100 (2026) Part D out-of-pocket cap limits annual exposure on the Part D pathway. Commercial: specialty coinsurance per plan; manufacturer copay support may apply for commercially insured patients (not government plans). Medicaid: nominal cost-share per state PDL.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

Lilly's patient assistance / copay support programs (e.g., Lilly Cares Foundation) may be available to commercially insured patients. Medicare and Medicaid beneficiaries are NOT eligible for manufacturer copay support under federal anti-kickback rules. Verify eligibility directly with Lilly.

Reduced copay through the assistance program, where eligible.

All figures are estimates. Actual cost-share depends on your specific Humana plan design and whether brand Forteo or generic teriparatide is listed as preferred. Verify your cost-share on the Humana member portal or by calling member services.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Look up teriparatide on your Humana plan drug list

    Log in to your Humana member account at humana.com and use the drug cost lookup tool. Search for both 'Forteo' (brand) and 'teriparatide' (generic) and 'Bonsity' to see which is listed, at what tier, and what the estimated cost-share is. Brand Forteo may appear as non-preferred or not listed if the generic is available at a lower tier on your specific plan.

  2. 2

    Confirm prior authorization criteria with your prescriber

    Ask your prescribing physician to check your Humana plan's prior authorization requirements for teriparatide. Most plans require documented severe osteoporosis and prior bisphosphonate trial or documented intolerance. Your prescriber submits the PA on your behalf; the PA typically covers 12–24 months and must be renewed. If brand Forteo is denied in favor of generic teriparatide, your prescriber can submit a medical exception if there is a documented clinical reason the generic is not appropriate.

  3. 3

    Ask about the $2,100 Part D cap and generic alternatives

    If teriparatide is approved on Part D, confirm your out-of-pocket exposure using the $2,100 (2026) annual cap — once you reach that cap, you pay $0 for the rest of the calendar year for all Part D covered drugs. Ask your prescriber whether generic teriparatide injection or Bonsity is clinically appropriate as a lower-cost alternative if brand Forteo is not covered on your plan.

If it's denied

Options if Humana won't cover Forteo

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Generic teriparatide injection

The preferred alternative to brand Forteo on most Humana formularies — same molecule, same daily subcutaneous injection, lower cost. Require the same PA and bisphosphonate-failure documentation as brand Forteo on most plans. Verify availability and tier on your specific Humana plan.

Bonsity (teriparatide-tjwp)

FDA-approved teriparatide biosimilar. Listed as preferred over brand Forteo on many formularies. Same mechanism, same injection schedule, PA required. Often Tier 3–4 on commercial plans versus brand Forteo at a non-preferred or excluded tier.

Prolia (denosumab) / Jubbonti

An alternative anabolic/antiresorptive pathway. Unlike Forteo (pharmacy benefit, daily injection), Prolia/Jubbonti is a medical-benefit q6-month clinic injection covered under Part B for most Humana Medicare members — a fundamentally different drug class, benefit rail, and dosing schedule. Discuss with your prescriber which is appropriate for your fracture-risk profile.

Reclast (zoledronic acid) / generic

Annual intravenous bisphosphonate infusion, administered in-office. Often required as the bisphosphonate trial before Forteo/teriparatide is approved. Covered under the medical benefit at typically lower cost than teriparatide.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

Brand Forteo is frequently non-preferred or not listed on Humana Medicare Part D formularies — most plans prefer generic teriparatide injection or Bonsity instead. You may be approved for the generic rather than the brand. Check your specific Humana plan drug list for the exact formulary status of brand Forteo versus generic teriparatide. If your prescriber has a clinical reason you need the brand specifically, a medical exception or prior authorization appeal can be filed.

Humana Part D plans typically require documented severe osteoporosis (T-score at or below -2.5 or fragility fracture history) and prior failure or intolerance of a bisphosphonate before approving teriparatide. If brand Forteo is requested and a generic alternative is available on formulary, an additional step-therapy requirement or medical exception may apply. PA approval periods are usually 12–24 months. Your prescriber submits the authorization; gather your DEXA scan results and prior treatment history before the request.

Yes. If teriparatide is covered under your Humana Medicare Part D or MA-PD plan, it is a Part D pharmacy-benefit drug — the $2,100 (2026) annual out-of-pocket cap applies. Once you reach that cap for the year, you pay $0 for covered Part D drugs for the rest of the calendar year. This is different from Prolia, which is a Part B medical-benefit drug where the Part D cap does not apply.

No, if you are enrolled in Humana Medicare or Medicaid. Federal anti-kickback rules prohibit Medicare and Medicaid beneficiaries from using manufacturer copay support programs, including Lilly's Forteo assistance. Most Humana members are on Medicare and cannot use these programs. Commercially insured Humana members may be eligible — verify directly with Eli Lilly. The Part D $2,100 cap is the main cost-protection mechanism for Medicare beneficiaries.

Forteo (teriparatide) and Prolia (denosumab) are both osteoporosis drugs but covered through entirely different pathways at Humana. Prolia is a medical-benefit Part B buy-and-bill office injection given every 6 months — for most Humana members it is cleanly covered at 20% Part B coinsurance, and the Part D cap does not apply. Forteo is a pharmacy-benefit Part D specialty drug, self-injected daily, and brand Forteo is often non-preferred in favor of generic teriparatide. The drugs serve different clinical needs — discuss with your prescriber which is appropriate.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Humana before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.